	del(5q) MDS
Myelodysplastic syndromes
Case studies
Lenalidomide
Transfusion-dependent
	transfusion independence
bone marrow microenvironment
erythroid response
complex karyotype
year-old woman
hemoglobin
MDS patients
grade 1 neutropenia
patients
transfusion-dependent
treatment
months
weeks
November
Repeat cytogenetic analyses
complete suppression
therapy
grade 2 thrombocytopenia
lenalidomide
cytogenetic responses
unexpected effects
additional chromosomal abnormalities
units
clinical trials
metaphases
chromosomal abnormalities
cytotoxic effect
normalization
unexpected
cytogenetic remission
effect

